Erratum: Opsonic and Antibody Responses to Pneumococcal Polysaccharide in Rheumatoid Arthritis Patients Receiving Golimumab plus Methotrexate (Medicine 94:52 (e2184) DOI: 10.1097/MD.0000000000002184);Opsonic and antibody responses to pneumococcal polysaccharide in rheumatoid arthritis patients receiving golimumab plus methotrexate

Medicine (United States)

Volumn 94, Issue 52, 2015, Pages

  Migita, Kiyoshi ^a   Akeda, Yukihiro ^b   Akazawa, Manabu ^c   Tohma, Shigeto ^a   Hirano, Fuminori ^a   Ideguchi, Haruko ^a   Matsumura, Ryutaro ^a   Suematsu, Eiichi ^a   Miyamura, Tomoya ^a   Mori, Shunsuke ^a   Fukui, Takahiro ^a   Izumi, Yasumori ^a   Iwanaga, Nozomi ^a   Jiuchi, Yuka ^a   Kozuru, Hideko ^a   Tsutani, Hiroshi ^a   Saisyo, Kouichirou ^a   Yamanaka, Takao ^a   Ohshima, Shiro ^a   Mori, Naoya ^a   Matsumori, Akinori ^a   Kitagawa, Kiyoki ^a   Takahi, Koichiro ^a   Ozawa, Tetsuo ^a   Hamada, Norikazu ^a   Nakajima, Kyoichi ^a   Nagai, Hideaki ^a   Tamura, Norio ^a   Suenaga, Yasuo ^a   Kawabata, Masaharu ^a   Matsui, Toshihiro ^a   Furukawa, Hiroshi ^a   Kawakami, Kenji ^a   Oish, Kazunori ^d   more..

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GOLIMUMAB; IMMUNOGLOBULIN G; METHOTREXATE; OPSONIN; PNEUMOCOCCUS VACCINE; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL SEROTYPES 6B; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION; ANTIBODY PRODUCTION; ARTHRITIS, RHEUMATOID; BLOOD; DRUG EFFECTS; DRUG MONITORING; IMMUNOLOGY; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; PROCEDURES; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 84954515545     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/01.md.0000481187.56983.62     Document Type: Erratum

References (30)

1. Winthrop KL. Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention. Rheum Dis Clin North Am. 2012;38:727-745.
2. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a popula-tion-based study. Arthritis Rheum. 2002;46:2287-2293.
3. Mohan AK, Coté TR, Siegel JN, et al. Infectious complications of biologic treatments of rheumatoid arthritis. Curr Opin Rheumatol. 2003;15:179-184.
4. Glück T, Müller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis. 2008;46:1459-1465.
5. Oishi K, Yoshimine H, Watanabe H, et al. Drug-resistant genes and serotypes of pneumococcal strains of community-acquired pneumonia among adults in Japan. Respirology. 2006;11:429-436.
6. Hua C, Barnetche T, Combe B, et al. Effect of methotrexate, anti-tumor necrosis factor a, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66:1016-1026.
7. Jansen AG, Rodenburg GD, van der Ende A, et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis. 2009;49:e23-e29.
8. van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414-422.
9. Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2010;62:917-928.
10. Song JY, Moseley MA, Burton RL, et al. Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother. 2013;19: 412-425.
11. Migita K, Akeda Y, Akazawa M, et al. Pneumococcal polysacchar-ide vaccination in rheumatoid arthritis patients receiving tacrolimus. Arthritis Res Ther. 2015;17:149.
12. Mori S, Ueki Y, Akeda Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis. 2013;72:1362-1366.
13. Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysacchar-ide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol. 2001;8:266-272.
14. Wernette CM, Frasch CE, Madore D, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003;10:514-519.
15. Burton RL, Nahm MH. Development and validation of a four-fold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol. 2006;13:1004-1009.
16. Brezinschek HP, Hofstaetter T, Leeb BF, et al. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate. Curr Opin Rheumatol. 2008;20:295-299.
17. Kaine JL, Kivitz AJ, Birbara C, et al. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 2007;34:272-279.
18. Kapetanovic MC, Saxne T, Sjöholm A, et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45:106-111.
19. Kivitz AJ, Schechtman J, Texter M, et al. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial. J Rheumatol. 2014;41:648-657.
20. Baxendale HE, Goldblatt D. Correlation of molecular characteristics, isotype, and in vitro functional activity of human antipneumococcal monoclonal antibodies. Infect Immun. 2006;74:1025-1031.
21. Park S, Nahm MH. Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect Immun. 2011;79:314-320.
22. Parkkali T, Väkeväinen M, Käyhty H, et al. Opsonophagocytic activity against Streptococcus pneumoniae type 19F in allogeneic BMT recipients before and after vaccination with pneumococcal polysaccharide vaccine. Bone Marrow Transplant. 2001;27:207-211.
23. Salinas GF, De Rycke L, Barendregt B, et al. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis. 2013;72:1037-1043.
24. Kobie JJ, Zheng B, Bryk P, et al. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther. 2011;13:R209.
25. Henckaerts I, Durant N, De Grave D, et al. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine. 2007;25:2518-2527.
26. Lee CJ, Lee LH, Frasch CE. Protective immunity of pneumococcal glycoconjugates. Crit Rev Microbiol. 2003;29:333-349.
27. Crnkic Kapetanovic M, Saxne T, Truedsson L, et al. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumo-coccal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res Ther. 2013;15:R1.
28. Nagel J, Geborek P, Saxne T, et al. The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients. Scand J Rheumatol. 2015;44:271-279.
29. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal poly-saccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816-819.
30. Romero-Steiner S, Frasch C, Concepcion N, et al. Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol. 2003;10:1019-1024.